Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Clinical trial NCT06253494 · RECRUITING
Trial details
- NCT number
- NCT06253494
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-14
- Primary completion
- 2026-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.